InsidersTradesSigma
Track the Castle Biosciences, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €904.9m. The latest transaction was disclosed on 14 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Derek Maetzold. Every trade is openly available.
Analysts rate Castle Biosciences, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$44.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Castle Biosciences, Inc. is a company focused on developing diagnostic tests for cancer, aiming to improve patient outcomes. It specializes in solutions based on genomics and molecular biology.